Selpercatinib in Treatment of Advanced Medullary Thyroid Cancer: Effectiveness and Side Effects – A Case Report of 2 Patients during 60 Months of Therapy
Case Reports in Oncology · 22.08.2026 · 19 (1) · 1512-1523
DOI: 10.1159/cro/abzag009 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 22.08.2026. Verfasst von Luciano Severgnini und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Internal Medicine II: Oncology and Hematology, Gastroenterology and Infective Disease, Landeskrankenhaus of Feldkirch, Feldkirch, Austri…. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Medullary thyroid carcinoma (MTC) is a rare, but aggressive tumor that accounts for 4% of thyroid carcinomas. A mutation in the proto-oncogene RET has been shown to occur in ca. 70% of those neoplasia. Selpercatinib is a newly approved drug that specifically targets the RET-kinase and demonstrated a very high efficacy in reducing the tumor activity and in progression-free survival in patients with an advanced metastatic disease [1]. Case Presentation: In accordance with the approval of the FDA, we started a treatment with selpercatinib on 2 patients with advanced metastatic MTC with an established RET mutation. They received selpercatinib 160 mg bidaily, and we observed the patients for 60 months. We observed a very good metabolic and serological response to the treatment with a decrease in the tumor marker of 99.8% and 98.5% and stable imaging. Hypertension grade II, hypotension grade I, proteinuria grade I, hyperphosphatemia grade I, and hypocalcemia grade II were the low-grade side effects that we observed during these 60 months of therapy.
Conclusion
Selpercatinib proved to be a good antineoplastic drug for patients with RET-mutated, advanced, and inoperable MTC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Internal Medicine II: Oncology and Hematology, Gastroenterology and Infective Disease, Landeskrankenhaus of Feldkirch, Feldkirch, Austria.
- University in Principality of Liechtenstein (UFL), Triesen, Liechtenstein.
- University and Oncological Center of Zurich, Swiss Tumor Immunology Institute, Zurich, Switzerland.
Zitieren
APA
Severgnini, L., Hartmann, B., Winder, D. T., Lang, T., Volgger, A., Benda, M., & Reimann, P. (2026). Selpercatinib in Treatment of Advanced Medullary Thyroid Cancer: Effectiveness and Side Effects – A Case Report of 2 Patients during 60 Months of Therapy. Case Reports in Oncology, 19(1), 1512-1523. https://doi.org/10.1159/cro/abzag009
Vancouver
Severgnini L, Hartmann B, Winder DT, Lang T, Volgger A, Benda M, et al. Selpercatinib in Treatment of Advanced Medullary Thyroid Cancer: Effectiveness and Side Effects – A Case Report of 2 Patients during 60 Months of Therapy. Case Reports in Oncology. 2026;19(1):1512-1523. doi:10.1159/cro/abzag009
BibTeX
@article{Severgnini2026,
author = {Severgnini, Luciano and Hartmann, Bernd and Winder, Doz Thomas and Lang, Theresia and Volgger, Andreas and Benda, Magdalena and Reimann, Patrick},
title = {Selpercatinib in Treatment of Advanced Medullary Thyroid Cancer: Effectiveness and Side Effects – A Case Report of 2 Patients during 60 Months of Therapy},
journal = {Case Reports in Oncology},
year = {2026},
volume = {19},
number = {1},
pages = {1512--1523},
doi = {10.1159/cro/abzag009}
}
EUVIMED